The CF-CIRC study: a French collaborative study to assess the accuracy of Cystic Fibrosis diagnosis in neonatal screening

<p>Abstract</p> <p>Background</p> <p>Cystic fibrosis (CF) is caused by mutations in the gene encoding for the CF transmembrane conductance regulator (CFTR) protein, which acts as a chloride channel after activation by cyclic AMP (cAMP). Newborn screening programs for CF...

Full description

Bibliographic Details
Main Authors: Bellon Gabriel, Reix Philippe, Huet Frédéric, Deneuville Eric, Bui Stéphanie, Roussel Delphine, Sermet-Gaudelus Isabelle, Lenoir Gérard, Edelman Aleksander
Format: Article
Language:English
Published: BMC 2006-10-01
Series:BMC Pediatrics
Online Access:http://www.biomedcentral.com/1471-2431/6/25
_version_ 1818394004447821824
author Bellon Gabriel
Reix Philippe
Huet Frédéric
Deneuville Eric
Bui Stéphanie
Roussel Delphine
Sermet-Gaudelus Isabelle
Lenoir Gérard
Edelman Aleksander
author_facet Bellon Gabriel
Reix Philippe
Huet Frédéric
Deneuville Eric
Bui Stéphanie
Roussel Delphine
Sermet-Gaudelus Isabelle
Lenoir Gérard
Edelman Aleksander
author_sort Bellon Gabriel
collection DOAJ
description <p>Abstract</p> <p>Background</p> <p>Cystic fibrosis (CF) is caused by mutations in the gene encoding for the CF transmembrane conductance regulator (CFTR) protein, which acts as a chloride channel after activation by cyclic AMP (cAMP). Newborn screening programs for CF usually consist of an immunoreactive trypsinogen (IRT) assay, followed when IRT is elevated by testing for a panel of CF-causing mutations. Some children, however, may have persistent hypertrypsinogenemia, only one or no identified CFTR gene mutation, and sweat chloride concentrations close to normal values. <it>In vivo </it>demonstration of abnormal CFTR protein function would be an important diagnostic aid in this situation. Measurements of transepithelial nasal potential differences (NPD) in adults accurately characterize CFTR-related ion transport. The aim of the present study is to establish reference values for NPD measurements for healthy children and those with CF aged 3 months to 3 years, the age range of most difficult-to-diagnose patients with suspected CF. The ultimate goal of our study is to validate NPD testing as a diagnostic tool for children with borderline results in neonatal screening.</p> <p>Methods/Design</p> <p>We adapted the standard NPD protocol for young children, designed a special catheter for them, used a slower perfusion rate, and shortened the protocol to include only measurement of basal PD, transepithelial sodium (Na<sup>+</sup>) transport in response to the Na<sup>+ </sup>channel inhibitor amiloride, and CFTR-mediated chloride (Cl<sup>-</sup>) secretion in response to isoproterenol, a β-agonist in a Cl<sup>- </sup>free solution.</p> <p>The study will include 20 children with CF and 20 healthy control children. CF children will be included only if they carry 2 CF-causing mutations in the <it>CFTR </it>gene or have sweat chloride concentrations > 60 mEq/L or both. The healthy children will be recruited among the siblings of the CF patients, after verification that they do not carry the familial mutation.</p> <p>Discussion</p> <p>A preliminary study of 3 adult control subjects and 4 children older than 12 years with CF verified that the new protocol was well tolerated and produced NPD measurements that did not differ significantly from those obtained with the standard protocol. This preliminary study will provide a basis for interpreting NPD measurements in patients with suspected CF after neonatal screening. Earlier definitive diagnosis should alleviate parental distress and allow earlier therapeutic intervention and genetic counseling.</p>
first_indexed 2024-12-14T05:54:19Z
format Article
id doaj.art-76e05b22b26942f88d26e4624ec87f93
institution Directory Open Access Journal
issn 1471-2431
language English
last_indexed 2024-12-14T05:54:19Z
publishDate 2006-10-01
publisher BMC
record_format Article
series BMC Pediatrics
spelling doaj.art-76e05b22b26942f88d26e4624ec87f932022-12-21T23:14:37ZengBMCBMC Pediatrics1471-24312006-10-01612510.1186/1471-2431-6-25The CF-CIRC study: a French collaborative study to assess the accuracy of Cystic Fibrosis diagnosis in neonatal screeningBellon GabrielReix PhilippeHuet FrédéricDeneuville EricBui StéphanieRoussel DelphineSermet-Gaudelus IsabelleLenoir GérardEdelman Aleksander<p>Abstract</p> <p>Background</p> <p>Cystic fibrosis (CF) is caused by mutations in the gene encoding for the CF transmembrane conductance regulator (CFTR) protein, which acts as a chloride channel after activation by cyclic AMP (cAMP). Newborn screening programs for CF usually consist of an immunoreactive trypsinogen (IRT) assay, followed when IRT is elevated by testing for a panel of CF-causing mutations. Some children, however, may have persistent hypertrypsinogenemia, only one or no identified CFTR gene mutation, and sweat chloride concentrations close to normal values. <it>In vivo </it>demonstration of abnormal CFTR protein function would be an important diagnostic aid in this situation. Measurements of transepithelial nasal potential differences (NPD) in adults accurately characterize CFTR-related ion transport. The aim of the present study is to establish reference values for NPD measurements for healthy children and those with CF aged 3 months to 3 years, the age range of most difficult-to-diagnose patients with suspected CF. The ultimate goal of our study is to validate NPD testing as a diagnostic tool for children with borderline results in neonatal screening.</p> <p>Methods/Design</p> <p>We adapted the standard NPD protocol for young children, designed a special catheter for them, used a slower perfusion rate, and shortened the protocol to include only measurement of basal PD, transepithelial sodium (Na<sup>+</sup>) transport in response to the Na<sup>+ </sup>channel inhibitor amiloride, and CFTR-mediated chloride (Cl<sup>-</sup>) secretion in response to isoproterenol, a β-agonist in a Cl<sup>- </sup>free solution.</p> <p>The study will include 20 children with CF and 20 healthy control children. CF children will be included only if they carry 2 CF-causing mutations in the <it>CFTR </it>gene or have sweat chloride concentrations > 60 mEq/L or both. The healthy children will be recruited among the siblings of the CF patients, after verification that they do not carry the familial mutation.</p> <p>Discussion</p> <p>A preliminary study of 3 adult control subjects and 4 children older than 12 years with CF verified that the new protocol was well tolerated and produced NPD measurements that did not differ significantly from those obtained with the standard protocol. This preliminary study will provide a basis for interpreting NPD measurements in patients with suspected CF after neonatal screening. Earlier definitive diagnosis should alleviate parental distress and allow earlier therapeutic intervention and genetic counseling.</p>http://www.biomedcentral.com/1471-2431/6/25
spellingShingle Bellon Gabriel
Reix Philippe
Huet Frédéric
Deneuville Eric
Bui Stéphanie
Roussel Delphine
Sermet-Gaudelus Isabelle
Lenoir Gérard
Edelman Aleksander
The CF-CIRC study: a French collaborative study to assess the accuracy of Cystic Fibrosis diagnosis in neonatal screening
BMC Pediatrics
title The CF-CIRC study: a French collaborative study to assess the accuracy of Cystic Fibrosis diagnosis in neonatal screening
title_full The CF-CIRC study: a French collaborative study to assess the accuracy of Cystic Fibrosis diagnosis in neonatal screening
title_fullStr The CF-CIRC study: a French collaborative study to assess the accuracy of Cystic Fibrosis diagnosis in neonatal screening
title_full_unstemmed The CF-CIRC study: a French collaborative study to assess the accuracy of Cystic Fibrosis diagnosis in neonatal screening
title_short The CF-CIRC study: a French collaborative study to assess the accuracy of Cystic Fibrosis diagnosis in neonatal screening
title_sort cf circ study a french collaborative study to assess the accuracy of cystic fibrosis diagnosis in neonatal screening
url http://www.biomedcentral.com/1471-2431/6/25
work_keys_str_mv AT bellongabriel thecfcircstudyafrenchcollaborativestudytoassesstheaccuracyofcysticfibrosisdiagnosisinneonatalscreening
AT reixphilippe thecfcircstudyafrenchcollaborativestudytoassesstheaccuracyofcysticfibrosisdiagnosisinneonatalscreening
AT huetfrederic thecfcircstudyafrenchcollaborativestudytoassesstheaccuracyofcysticfibrosisdiagnosisinneonatalscreening
AT deneuvilleeric thecfcircstudyafrenchcollaborativestudytoassesstheaccuracyofcysticfibrosisdiagnosisinneonatalscreening
AT buistephanie thecfcircstudyafrenchcollaborativestudytoassesstheaccuracyofcysticfibrosisdiagnosisinneonatalscreening
AT rousseldelphine thecfcircstudyafrenchcollaborativestudytoassesstheaccuracyofcysticfibrosisdiagnosisinneonatalscreening
AT sermetgaudelusisabelle thecfcircstudyafrenchcollaborativestudytoassesstheaccuracyofcysticfibrosisdiagnosisinneonatalscreening
AT lenoirgerard thecfcircstudyafrenchcollaborativestudytoassesstheaccuracyofcysticfibrosisdiagnosisinneonatalscreening
AT edelmanaleksander thecfcircstudyafrenchcollaborativestudytoassesstheaccuracyofcysticfibrosisdiagnosisinneonatalscreening
AT bellongabriel cfcircstudyafrenchcollaborativestudytoassesstheaccuracyofcysticfibrosisdiagnosisinneonatalscreening
AT reixphilippe cfcircstudyafrenchcollaborativestudytoassesstheaccuracyofcysticfibrosisdiagnosisinneonatalscreening
AT huetfrederic cfcircstudyafrenchcollaborativestudytoassesstheaccuracyofcysticfibrosisdiagnosisinneonatalscreening
AT deneuvilleeric cfcircstudyafrenchcollaborativestudytoassesstheaccuracyofcysticfibrosisdiagnosisinneonatalscreening
AT buistephanie cfcircstudyafrenchcollaborativestudytoassesstheaccuracyofcysticfibrosisdiagnosisinneonatalscreening
AT rousseldelphine cfcircstudyafrenchcollaborativestudytoassesstheaccuracyofcysticfibrosisdiagnosisinneonatalscreening
AT sermetgaudelusisabelle cfcircstudyafrenchcollaborativestudytoassesstheaccuracyofcysticfibrosisdiagnosisinneonatalscreening
AT lenoirgerard cfcircstudyafrenchcollaborativestudytoassesstheaccuracyofcysticfibrosisdiagnosisinneonatalscreening
AT edelmanaleksander cfcircstudyafrenchcollaborativestudytoassesstheaccuracyofcysticfibrosisdiagnosisinneonatalscreening